Rheumatology

New research shows clinical effectiveness in increasing biologic doses in children, depending on the agent.

Rheumatology Network interviewed Hermine Brunner, MD, MSc, MBA, lead investigator of the JUNIPERA study, which reported on the safety and efficacy of secukinumab for patients with juvenile idiopathic arthritis (JIA), presented at the EULAR 2021 Virtual Congress. Secukinumab was the first approved biologic for specific JIA categories in the US and marked improvement of skin involvement with juvenile spondyloarthritis (jPSA) and increased quality of life for children with chronic arthritis plus psoriasis.

A new study builds upon previous insights and contributes to the growing trend of probiotic treatment in young patients.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 18, 2021.

A new study shows an increase in same or next day admissions in patients who opt for home infusions.

Rheumatology Network sat down with Mehret Birru Talabi, MD, PhD, to discuss the recent study published in ACR Open Rheumatology entitled, “Tough choices: Exploring medication decision-making during pregnancy and lactation among women with inflammatory arthritis.”

Investigators push for messaging transparency and consistency from health care professionals in regard to arthritis medication.

In patients with psoriatic arthritis (PsA), guselkumab (Tremfya, Janssen Immunology) treatment reduced serum protein levels of acute phase and T-helper cell 17 (Th17) effector cytokines, achieving comparable levels to those in healthy controls.

Jeffrey Stark, MD, discusses the statement UCB issued endorsing the creation of a new sub-category (M.45A) for non-radiographical axial spondyloarthritis (nr-axSpA).

The risk was generally did not depend on whether the initial fracture was deemed traumatic or nontraumatic.

In today's episode, we sat down with Daniel Hernandez, MD, and Shilpa Venkatachalam, PhD, MPH, of CreakyJoints, to highlight health disparities in marginalized communities and introduce their exciting new venture, CreakyJoints Espanol.

The American College of Rheumatology (ACR) published its long-awaited update to the 2015 Guidelines on the Management of Rheumatoid Arthritis last week. Have you read the 2021 update yet? Test your knowledge of the most important points with our quiz.

In partnership with CreakyJoints, Alexis Ogdie, MD discusses her study, “Real-World Patient Experience and Treatment Preferences in Patients With Psoriatic Arthritis,” which was recently presented at the EULAR 2021 Virtual Congress.

Investigators study loci and the hereditary nature of the disease, which was categorized as a global health priority by the WHO 3 years ago.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 11, 2021.

Liana Fraenkel, MD, MPH, discusses the recent updates to the American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis, for which she served as part of the Core Leadership Team.

Risankizumab showed significantly greater improvements in symptoms of psoriatic arthritis when compared with a placebo and was well tolerated in patients who were intolerant to biologics and conventional synthetic disease-modifying antirheumatic drugs.

Rheumatology Network sat down with Eugen Feist, MD, to discuss the recent olokizumab data including the therapeutic prospects for olokizumab, its unique biologic mode of action, and the clinical significance of the phase III studies.

Boston investigators observe increased kidney injury and risk of ventilation among infected immunocompromised patients.

Of the 44 new recommendations, 7 were strongly recommended.

The American College of Rheumatology has updated its treatment guidelines for rheumatoid arthritis. The guideline includes 44 treatment recommendations, 7 of which are now strongly recommended.

Rheumatology Network spoke with Jessica Walsh, MD, to discuss her study, “Patient perspectives of biologic treatments for axial spondyloarthritis: satisfaction, wear-off between doses, and use of supplemental medications."

Alyssa Johnsen, MD, PhD, spoke with Rheumatology Network about the efficacy of guselkumab for psoriatic arthritis, the challenges of delivering safe and effective treatments in this patient population, and how guselkumab can help improve physical, social, and work activity for these patients.

Rheumatology Network sat down for an interview with Benjamin Nowell, PhD, in partnership with CreakyJoints, to discuss the Healthy Mind Healthy You study, which assessed 2 mindfulness programs of varying lengths, designed for people with rheumatic disease, and compared the results.

In addition to swollen joint count, joint location and functional impairment should also be considered when describing psoriatic arthritis as moderate.

An expert rheumatologist shares key insights into common causes, typical presentation, and differential diagnosis of systemic lupus erythematous (SLE) and idiopathic inflammatory myopathies.

Rheumatology Network sat down with Pedro Machado, MD, PhD, to discuss his EULAR 2021 presentation entitled, “COVID-19 vaccine safety in patients with rheumatic and musculoskeletal disease.”

Kostas N. Botsoglou, MD, provides an overview of systemic autoimmune rheumatic diseases (SARDs) or connective tissue diseases by discussing their overall characteristics, common comorbidities, and impact on patient quality of life.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 4, 2021.

Roy Fleischmann, MD, discusses his presentations for EULAR 2021, which include topics about the side effects of JAK inhibitors, disease activity measures of methotrexate withdrawal among patients with rheumatoid arthritis, and the long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis.